NEWTOWN, Pa., Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ:SLNO), resulting from allegations of providing potentially misleading business information to the investing public.
If you have information that could assist in the Soleno Investigation or if you are a Soleno investor who suffered a loss and would like to learn more, you can provide your information HERE.
You can also contact attorney Eric Lechtzin of Edelson Lechtzin LLP by calling 844-563-5550 ext. 1, or via e-mail at elechtzin@edelson-law.com.
THE COMPANY:
Soleno Therapeutics is a biopharmaceutical company dedicated to creating innovative treatments for rare diseases.
THE ALLEGED WRONGDOING:
On March 26, 2025, the FDA authorized Soleno's VYKAT XR (diazoxide choline) for treating hyperphagia in patients four years and older with Prader-Willi syndrome. By November 4, 2025, Soleno announced an 8% discontinuation rate caused by side effects and stated that a short-seller report from mid-August had delayed the drug's rollout. Subsequently, Soleno's stock price dropped by over 26%.
ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class and collective litigation alleging violations of the federal antitrust laws, ERISA employee benefit plans, wage theft and unpaid overtime, consumer fraud, and dangerous and defective drugs and medical devices.
For more information, please contact:
Marc H. Edelson, Esq.
Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: medelson@edelson-law.com
Email: elechtzin@edelson-law.com
Web: www.edelson-law.com
This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
View original content to download multimedia:https://www.prnewswire.com/news-releases/investigation-alert-edelson-lechtzin-llp-announces-investigation-of-soleno-therapeutics-inc-nasdaq-slno-and-encourages-investors-with-substantial-losses-or-witnesses-with-relevant-information-to-contact-the-firm-302610583.html
SOURCE Edelson Lechtzin LLP
